TD Asset Management’s Sophiris Bio, Inc. SPHS Stock Holding History

TD Asset Management’s Portfolio SPHS Stock Details SPHS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-58,850	Closed	-$172K	–	1431
2014 Q3	$172K	Hold	58,850	–	–	﹤0.01%	1269
2014 Q2	$132K	Hold	58,850	–	–	﹤0.01%	1266
2014 Q1	$196K	Hold	58,850	–	–	﹤0.01%	1248
2013 Q4	$218K	Hold	58,850	–	–	﹤0.01%	1213
2013 Q3	$275K	Buy	+58,850	New	+$271K	﹤0.01%	1136

Other funds holding SPHS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

TD Asset Management's SPHS Position: Q4 2014 in Review

TD Asset Management sold out of Sophiris Bio, Inc. (SPHS) in Q4 2014, closing a stake of 58,850 shares — an estimated $172K sold.

TD Asset Management first reported a position in SPHS in Q3 2013 and held it in 5 quarters. The position peaked at $275K in Q3 2013. 14 funds tracked by Wall St. Rank hold SPHS as of Q4 2014.

TD Asset Management reported no remaining Sophiris Bio, Inc. position as of Q4 2014 after selling out during the quarter.
TD Asset Management sold 58,850 Sophiris Bio, Inc. shares in Q4 2014, an estimated $172K.
TD Asset Management first reported a position in Sophiris Bio, Inc. in Q3 2013 and held it in 5 quarters.
TD Asset Management's Sophiris Bio, Inc. position peaked at $275K in Q3 2013.
14 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q4 2014.

Based on TD Asset Management's 13F filing for Q4 2014, filed 30 Jan 2015.